conference Archives - Page 2 of 13

WCLC 2023 : Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC

By Peng Geng 2023.10.23

On the final day of the 2023 World Conference on Lung Cancer (WCLC) , Oncology Frontier had the privilege of interviewing Dr. Wu Yilong from Guangdong Provincial People's Hospital, Dr. Cheng Ying from Jilin Cancer Hospital, and Dr. Han Baohui from Shanghai Chest Hospital. These three experts participated in a dialogue and discussion regarding hot topics at the conference and significant clinical research. Here present the highlights of their on-site discussions.

WCLC 2023 | Dr. Liu: Immunotherapy Combined Chemotherapy Can Bring Long-term Survival Benefits to ES-SCLC Patients

By Peng Geng 2023.10.23

The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9th to 12th. Dr. Stephen V. Liu from Georgetown University presented an important study (Abstract No: OA01.04) on the long-term follow-up results of first-line immunotherapy combined with chemotherapy in ES-SCLC patients. Oncology Frontier invited Dr. Liu to highlight his presentation at the conference.

WCLC 2023 | Dr. Chen Haiquan: The Asian Perspective on Lung Cancer Screening

By Peng Geng 2023.10.23

The 2023 World Conference on Lung Cancer (WCLC) was held at the Singapore Expo. On the first day, Dr. Chen Haiquan, Director of the Lung Cancer Research Center at Fudan University and Chief of Thoracic Surgery at Fudan University Affiliated Tumor Hospital, gave an important presentation. During an interview with "Oncology Frontier", Dr. Chen Haiquan shared the key points of his presentation.

WCLC 2023 | Dr. Han Baohui’s Team Presents Multiple Research Achievements, Making China’s Voice Resonate at WCLC

By Peng Geng 2023.10.23

The 2023 World Conference on Lung Cancer (WCLC) was held at the Singapore Expo, attracted over 6,000 participants from various fields of basic and clinical science related to thoracic malignancies. The conference received approximately 1,800 abstracts, featured over 350 invited lectures, 150 oral presentations, mini-oral presentations, and more than 1,500 posters and electronic posters, showcased the latest advancements in the field of thoracic oncology.

WCLC 2023 | Dr. Shi Meiqi: Treatment Strategies for EGFR Mutation and KRAS Mutation Non-Small Cell Lung Cancer

By Peng Geng 2023.10.23

The 2023 World Lung Cancer Congress (WCLC) took place at the Singapore Expo Center from September 9th to 12th. Dr. Shi Meiqi from Jiangsu Cancer Hospital presented crucial findings in a phase 1/2 clinical study at this conference (MA15.09). In an interview with " Oncology Frontier ," Dr. Shi Meiqi shared research insights, key results, and treatment strategies for KRAS mutation non-small cell lung cancer patients.

WCLC Voice of China | Dr. Liang Application of Video-Based Artificial Intelligence in Thoracoscopic Lobectomy for Lung Cancer

By Peng Geng 2023.10.23

From September 9th to 12th, 2023, the World Conference on Lung Cancer (WCLC) was held in Singapore. Oncology Frontier deeply engaged in the conference, capturing the latest advancements and witnessing the progress and strides made by China in the international oncology arena. Dr. Liang Hengrui of the First Affiliated Hospital of Guangzhou Medical University presented the results from Chinese researchers in the field of "Artificial Intelligence Application in Thoracoscopic Lobectomy for Lung Cancer" in a brief oral report at the 2023 WCLC.

WCLC Voice of China | Dr. Xie Huikang: The Value of Lepidic and Invasion Patterns New Diagnostic Criteriafor the Differential Diagnosis of AIS, MIA from Invasive Adenocarcinoma

By Peng Geng 2023.10.23

At the 2023 World Conference on Lung Cancer (WCLC), Dr. Xie Huikang from Shanghai Pulmonary Hospital presented a study titled " The Value of Lepidic and Invasion Pattern NEW Diagnostic Criteria for the Differential Diagnosis of AIS, MIA from Invasive Adenocarcinoma ." The study aimed to explore whether the new IASLC definitions and standards had an impact on the diagnosis of AIS, MIA, and IAC compared to previous criteria.

WCLC 2023 |Dr. Zhu Zhengfei: SBRT Combined with Dual Immune Checkpoint Inhibitors for Advanced NSCLC Achieves a Median OS of 34 Months

By Peng Geng 2023.10.23

The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), was held in Singapore from September 9th to 12th. " Oncology Frontier" invited Zhu Zhengfei from Fudan University-affiliated Cancer Hospital to comment on the findings of the COSINR study.

New Insights from EASL: The Role of Lifestyle Interventions in Preventing and Treating NAFLD/NASH in Children and Adults

By Xiaorong JI 2023.10.23

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease globally and is independently associated with an increased risk of Type 2 Diabetes (T2DM) and cardiovascular diseases. Approximately one-third of the global population is currently facing the health threat posed by NAFLD, yet it appears that healthcare systems are not giving it enough attention. On the first day of the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023, Doctor Elisabetta Bugianesi from the Department of Digestive Internal Medicine at the University of Turin, Italy, urged the public to take NAFLD seriously. She provided a detailed overview of lifestyle interventions as a key means of preventing and treating NAFLD, sharing the latest research evidence, guideline recommendations, and future strategies. Hepatology Digest has compiled this report for the benefit of its readers.

Dr. Lu Si: mRNA Vaccines and TIGIT Monoclonal Antibodies — New Stars of 2023 AACR

By Peng Geng 2023.10.23

PD-1 inhibitors have become the international standard for adjuvant treatment of stage IIB-IV melanoma after surgery. Research on the neoadjuvant use of PD-1 monotherapy (pembrolizumab) for resectable melanoma was just published in the New England Journal of Medicine in March of this year. With this, PD-1 inhibitors cover the two major treatment areas of neoadjuvant and adjuvant treatment of melanoma. Two studies presented at this year's AACR conference have brought new breakthroughs to this field.